argenx SE
NASDAQ:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
NASDAQ:ARGX
Watchlist
Price: 843.26 USD -3.95%
Market Cap: 50.4B USD
Section:
 

Relative Value

The Relative Value of one ARGX stock under the Base Case scenario is hidden USD. Compared to the current market price of 843.26 USD, argenx SE is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ARGX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

14.1
P/S
P/S
Price to Sales
14.1
vs History
12
vs Industry
34
Median 3Y
0
Median 5Y
0
Industry
7.9
Forward
12
More Details
33.1
P/E
P/E
Price to Earnings
33.1
vs History
7
vs Industry
4
Median 3Y
0
Median 5Y
0
Industry
23.7
Forward
46.4
More Details
124.7
P/OCF
P/OCF
Price to OCF
124.7
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
22
More Details
167.4
P/FCFE
P/FCFE
Price to FCFE
167.4
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
23.8
More Details
8.3
P/B
P/B
Price to Book Value
8.3
vs History
9
vs Industry
11
Median 3Y
7.3
Median 5Y
5.6
Industry
3.3
More Details
13.2
EV/S
EV/S
Enterprise Value to Sales
13.2
vs History
11
vs Industry
30
Median 3Y
0
Median 5Y
0
Industry
8.3
Forward
11.1
More Details
14.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.7
vs History
15
vs Industry
29
Median 3Y
0
Median 5Y
0
Industry
10.1
More Details
57.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
57.8
vs History
20
vs Industry
0
Median 3Y
0
Median 5Y
0
Industry
6.4
Forward
38.3
More Details
59.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
59.4
vs History
11
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7
Forward
41.1
More Details
117.7
EV/OCF
EV/OCF
Enterprise Value to OCF
117.7
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
More Details
153.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
153.9
vs History
1
vs Industry
Median 3Y
0
Median 5Y
0
Industry
6.5
More Details
17.5
EV/IC
EV/IC
Enterprise Value to IC
17.5
vs History
9
vs Industry
10
Median 3Y
9.6
Median 5Y
5.4
Industry
5.7
More Details

Multiples Across Competitors

ARGX Competitors Multiples
argenx SE Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
argenx SE
NASDAQ:ARGX
43.8B USD 14.1 33.1 57.8 59.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
400.7B USD 6.7 170.6 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
172.3B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
149.8B USD 5.2 18.7 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 9.8 31.3 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD 5.6 17.4 16.5 18.8
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.4 1 213.7 158 191.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.4 -59.9
P/S Multiple
Revenue Growth P/S to Growth
NL
argenx SE
NASDAQ:ARGX
Average P/S: 3 073 825.3
14.1
49%
0.3
FR
Pharnext SCA
OTC:PNEXF
33 809 907.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 083.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
NL
argenx SE
NASDAQ:ARGX
Average P/E: 191.1
33.1
40%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.7
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 213.7
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBITDA: 39.4
57.8
839%
0.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBIT: 45.5
59.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.9 N/A N/A

See Also

Summary
ARGX intrinsic value, competitors valuation, and company profile.
DCF Valuation
ARGX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ARGX stock valuation using valuation multiples.
Wall Street Estimates
ARGX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ARGX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.